Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal pati...

Full description

Bibliographic Details
Main Authors: Robertson, John F.R., Bondarenko, Igor M., Trishkina, Ekaterina, Dvorkin, Mikhail, Panasci, Lawrence, Manikhas, Alexey, Shparyk, Yaroslav, Cardona-Huerta, Servando, Cheung, Kwok-Leung, Philco-Salas, Manuel Jesus, Ruiz-Borrego, Manuel, Shao, Zhimin, Noguchi, Shinzaburo, Rowbottom, Jacqui, Stuart, Mary, Grinsted, Lynda M., Fazal, Mehdi, Ellis, Matthew J.
Format: Article
Published: Elsevier 2017
Online Access:https://eprints.nottingham.ac.uk/39236/

Internet

https://eprints.nottingham.ac.uk/39236/

Similar Items